Tags

Type your tag names separated by a space and hit enter

Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms.

Abstract

BACKGROUND

Epidemiological and animal studies have suggested that dietary fish or fish oil rich in omega-3 fatty acids (omega3), docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), may have effects in psychiatric and behavioral symptoms in Alzheimer's disease (AD). An association with APOEomega4 carriers and neuropsychiatric symptoms in AD has also been suggested.

OBJECTIVE

To determine effects of dietary omega3 supplementation to AD patients with mild to moderate disease on psychiatric and behavioral symptoms, daily functions and a possible relation to APOEgenotype.

METHODS

Randomized, double-blind, placebo-controlled clinical trial where 204 AD patients (74+/-9 years) with acetylcholine esterase inhibitor treatment and a MMSE>15 points were randomized to daily intake of 1.7 g DHA and 0.6 g EPA (omega3 group) or placebo for 6 months. Then, all received the omega3 supplementation for 6 more months. Neuropsychiatric symptoms were measured with Neuropsychiatric Inventory (NPI) and Montgomery Asberg Depression Scale (MADRS). Caregivers burden and activities of daily living (Disability Assessment for Dementia, DAD) were also assessed.

RESULTS

One hundred and seventy-four patients fulfilled the trial. 72% were APOEomega4 carriers. No significant overall treatment effects on neuropsychiatric symptoms, on activities of daily living or on caregiver's burden were found. However, significant positive treatment effects on the scores in the NPI agitation domain in APOEomega4 carriers (p=0.006) and in MADRS scores in non-APOEomega4 carriers (p=0.005) were found.

CONCLUSIONS

Supplementation with omega3 in patients with mild to moderate AD did not result in marked effects on neuropsychiatric symptoms except for possible positive effects on depressive symptoms (assessed by MADRS) in non-APOEomega4 carriers and agitation symptoms (assessed by NPI) in APOEomega4 carriers. ClinicalTrials.gov identifier: NCT00211159

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of NVS, Section of Clinical Geriatrics, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden. Yvonne.Freund-Levi@ki.se

    , , , , , , , ,

    Source

    MeSH

    Activities of Daily Living
    Aged
    Alzheimer Disease
    Analysis of Variance
    Apolipoproteins E
    Cholinesterase Inhibitors
    Depression
    Dietary Supplements
    Donepezil
    Double-Blind Method
    Fatty Acids, Omega-3
    Female
    Galantamine
    Genotype
    Humans
    Indans
    Male
    Phenylcarbamates
    Piperidines
    Psychiatric Status Rating Scales
    Rivastigmine
    Statistics, Nonparametric
    Treatment Outcome

    Pub Type(s)

    Journal Article
    Randomized Controlled Trial
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    17582225

    Citation

    Freund-Levi, Yvonne, et al. "Omega-3 Supplementation in Mild to Moderate Alzheimer's Disease: Effects On Neuropsychiatric Symptoms." International Journal of Geriatric Psychiatry, vol. 23, no. 2, 2008, pp. 161-9.
    Freund-Levi Y, Basun H, Cederholm T, et al. Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. Int J Geriatr Psychiatry. 2008;23(2):161-9.
    Freund-Levi, Y., Basun, H., Cederholm, T., Faxén-Irving, G., Garlind, A., Grut, M., ... Eriksdotter-Jönhagen, M. (2008). Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry, 23(2), pp. 161-9.
    Freund-Levi Y, et al. Omega-3 Supplementation in Mild to Moderate Alzheimer's Disease: Effects On Neuropsychiatric Symptoms. Int J Geriatr Psychiatry. 2008;23(2):161-9. PubMed PMID: 17582225.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. AU - Freund-Levi,Yvonne, AU - Basun,Hans, AU - Cederholm,Tommy, AU - Faxén-Irving,Gerd, AU - Garlind,Anita, AU - Grut,Mikaela, AU - Vedin,Inger, AU - Palmblad,Jan, AU - Wahlund,Lars-Olof, AU - Eriksdotter-Jönhagen,Maria, PY - 2007/6/22/pubmed PY - 2008/8/14/medline PY - 2007/6/22/entrez SP - 161 EP - 9 JF - International journal of geriatric psychiatry JO - Int J Geriatr Psychiatry VL - 23 IS - 2 N2 - BACKGROUND: Epidemiological and animal studies have suggested that dietary fish or fish oil rich in omega-3 fatty acids (omega3), docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), may have effects in psychiatric and behavioral symptoms in Alzheimer's disease (AD). An association with APOEomega4 carriers and neuropsychiatric symptoms in AD has also been suggested. OBJECTIVE: To determine effects of dietary omega3 supplementation to AD patients with mild to moderate disease on psychiatric and behavioral symptoms, daily functions and a possible relation to APOEgenotype. METHODS: Randomized, double-blind, placebo-controlled clinical trial where 204 AD patients (74+/-9 years) with acetylcholine esterase inhibitor treatment and a MMSE>15 points were randomized to daily intake of 1.7 g DHA and 0.6 g EPA (omega3 group) or placebo for 6 months. Then, all received the omega3 supplementation for 6 more months. Neuropsychiatric symptoms were measured with Neuropsychiatric Inventory (NPI) and Montgomery Asberg Depression Scale (MADRS). Caregivers burden and activities of daily living (Disability Assessment for Dementia, DAD) were also assessed. RESULTS: One hundred and seventy-four patients fulfilled the trial. 72% were APOEomega4 carriers. No significant overall treatment effects on neuropsychiatric symptoms, on activities of daily living or on caregiver's burden were found. However, significant positive treatment effects on the scores in the NPI agitation domain in APOEomega4 carriers (p=0.006) and in MADRS scores in non-APOEomega4 carriers (p=0.005) were found. CONCLUSIONS: Supplementation with omega3 in patients with mild to moderate AD did not result in marked effects on neuropsychiatric symptoms except for possible positive effects on depressive symptoms (assessed by MADRS) in non-APOEomega4 carriers and agitation symptoms (assessed by NPI) in APOEomega4 carriers. ClinicalTrials.gov identifier: NCT00211159 SN - 0885-6230 UR - https://www.unboundmedicine.com/medline/citation/17582225/Omega_3_supplementation_in_mild_to_moderate_Alzheimer's_disease:_effects_on_neuropsychiatric_symptoms_ L2 - https://doi.org/10.1002/gps.1857 DB - PRIME DP - Unbound Medicine ER -